Regulation of therapeutic protein release in response to circadian biomarkers

Nature Communications, Published online: 06 November 2025; doi:10.1038/s41467-025-64761-9 Circadian clocks integrate external environmental and internal physiological cues to generate oscillations of secreted endocrine signals. Here the authors build a melatonin-based circadian biomarker-driven gene switch in mammalian cells for type-2 diabetes treatment by oscillatory GLP-1 release.

Costs for Zepbound, Wegovy Could Drop Soon: What to Know

The White House is in discussions with the makers of weight loss drugs Wegovy and Zepbound to drastically lower prices, NBC News has learned. The prices could drop from an average price of $1,300 a month to $150 a month, according to sources familiar with the plan. It remains unclear who would be eligible. NBC’s Vicky Nguyen joins TODAY to break down the details.

“The race is on to turn your body into a GLP-1 factory “

I hate to quote CNN, but: https://www.cnn.com/2025/11/04/health/obesity-glp1-gene-therapy-research “RenBio calls its technology “Make Your Own,” and it’s a relatively simple idea. They use a plasmid — a ring of naked DNA — in saline solution. … In RenBio’s case, the researchers spelled out the instructions to make a GLP-1 receptor agonist protein — essentially the same […]

Earnings whiplash: Tesla’s $1T vote; Robinhood’s 100% rev; Palantir & Novo slip

News snapshot Volatile earnings tape today: big beats, surprise cuts, and one of tech’s highest‑stakes votes. From Robinhood’s 100% revenue jump to Tesla’s $1T pay showdown, sentiment is split. Quick hits: – Tesla (TSLA): Musk’s ~$1T pay package faces major investor/proxy pushback ahead of the vote; shares ~-3% on governance/dilution worries. – Robinhood (HOOD): Q3 […]